Regulatory Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe Pharmaceutical TechnologyLilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults.OncologyRead full story pharminent June 29, 2026 (Last updated: June 29, 2026) Pharmaceutical Technology Lilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults. Oncology Read full story Post navigation Previous: Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and ZepboundNext: Ipsen charts $1.75bn course for Kartos acquisition Related Stories Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug pharminent August 31, 2026 Regulatory FDA green lights Priovant drug for rare skin disease pharminent August 28, 2026 Regulatory Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 pharminent August 26, 2026